News

Read about the progress of individual NINDS PDBP projects and learn about presentations and workshops that are relevant to the PDBP.
Genetic deletion of Polo-like kinase 2 reduces alpha-synuclein serine-129 phosphorylation in presynaptic terminals but not Lewy bodies.

  • Weston LJ
  • Stackhouse TL
  • Spinelli KJ
  • Boutros SW
  • Rose EP
  • Osterberg VR
  • Luk KC
  • Raber J
  • Weissman TA
  • Unni VK
iPSC for modeling neurodegenerative disorders.

  • Valadez-Barba V
  • Cota-Coronado A
  • Hernández-Pérez OR
  • Lugo-Fabres PH
  • Padilla-Camberos E
  • Díaz NF
  • Díaz-Martínez NE
Evaluation of blood flow as a route for propagation in experimental synucleinopathy.

  • Yu X
  • Persillet M
  • Zhang L
  • Zhang Y
  • Xiuping S
  • Li X
  • Ran G
  • Breger LS
  • Dovero S
  • Porras G
  • Dehay B
  • Bezard E
  • Qin C
Cutaneous sensory and autonomic denervation in Progressive Supranuclear Palsy.

  • Dubbioso R
  • Provitera V
  • Vitale F
  • Stancanelli A
  • Borreca I
  • Caporaso G
  • De Michele G
  • De Rosa A
  • Picillo M
  • Barone P
  • Iodice R
  • Manganelli F
  • De Michele G
  • Santoro L
  • Nolano M
MicroRNA‑34a‑5p expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson's disease: An exploratory study.

  • Grossi I
  • Radeghieri A
  • Paolini L
  • Porrini V
  • Pilotto A
  • Padovani A
  • Marengoni A
  • Barbon A
  • Bellucci A
  • Pizzi M
  • Salvi A
  • De Petro G
Quantification of Blood Caffeine Levels in Patients With Parkinson's Disease and Multiple System Atrophy by Caffeine ELISA.

  • Ohmichi T
  • Kasai T
  • Shinomoto M
  • Matsuura J
  • Koizumi T
  • Kitani-Morii F
  • Tatebe H
  • Sasaki H
  • Mizuno T
  • Tokuda T
Mild Cognitive Impairment at Risk for Lewy Body Dementia.

  • Chen Q
  • Lowe VJ
  • Boeve BF
  • Przybelski SA
  • Miyagawa T
  • Senjem ML
  • Jack CR Jr
  • Lesnick TG
  • Kremers WK
  • Fields JA
  • Min HK
  • Schwarz CG
  • Gunter JL
  • Graff-Radford J
  • Savica R
  • Knopman DS
  • Jones D
  • Ferman TJ
  • Graff-Radford NR
  • Petersen RC
  • Kantarci K
Increase of Prokineticin-2 in Serum of Patients with Parkinson's Disease.

  • Schirinzi T
  • Maftei D
  • Pieri M
  • Bernardini S
  • Mercuri NB
  • Lattanzi R
  • Severini C
The Antiviral Drug Tilorone Is a Potent and Selective Inhibitor of Acetylcholinesterase.

  • Vignaux PA
  • Minerali E
  • Lane TR
  • Foil DH
  • Madrid PB
  • Puhl AC
  • Ekins S
Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study.

  • Attems J
  • Toledo JB
  • Walker L
  • Gelpi E
  • Gentleman S
  • Halliday G
  • Hortobagyi T
  • Jellinger K
  • Kovacs GG
  • Lee EB
  • Love S
  • McAleese KE
  • Nelson PT
  • Neumann M
  • Parkkinen L
  • Polvikoski T
  • Sikorska B
  • Smith C
  • Grinberg LT
  • Thal DR
  • Trojanowski JQ
  • McKeith IG
Plasma-borne indicators of inflammasome activity in Parkinson's disease patients.

  • Anderson FL
  • von Herrmann KM
  • Andrew AS
  • Kuras YI
  • Young AL
  • Scherzer CR
  • Hickey WF
  • Lee SL
  • Havrda MC
SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses.

  • Pilotto A
  • Masciocchi S
  • Volonghi I
  • De Giuli V
  • Caprioli F
  • Mariotto S
  • Ferrari S
  • Bozzetti S
  • Imarisio A
  • Risi B
  • Premi E
  • Benussi A
  • Focà E
  • Castelli F
  • Zanusso G
  • Monaco S
  • Stefanelli P
  • Gasparotti R
  • Zekeridou A
  • McKeon A
  • Ashton NJ
  • Blennov K
  • Zetterberg H
  • Padovani A
Spectral Characteristics of subthalamic Nucleus local Field Potentials in parkinson's disease: Phenotype and Movement matter.

  • Godinho F
  • Fim Neto A
  • Bianqueti BL
  • de Luccas JB
  • Varjão E
  • Terzian Filho PR
  • Figueiredo EG
  • Almeida TP
  • Yoneyama T
  • Takahata AK
  • Rocha MS
  • Soriano DC

Press releases, workshop summaries, and editorials

NINDS Parkinson's Disease Biomarkers Program Consortium Meeting, Bethesda MD (August 12-13, 2019)

The PDBP Annual Consortium Meeting was held August 12-13, 2019 in Rockville, MD.  Principal investigators (PIs), clinical and data management experts from each PDBP project, and representatives from the  NIH, PD nonprofit organizations , and the pharmaceutical industry met to discuss progress over the last twelve months in addition to current and future plans for the program.

Accelerating Medicines Partnership launches data knowledge portal for Parkinson’s disease

Shared platform to catalyze research collaboration toward biomarker discovery to advance the development disease therapies

AMP PD

The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease. The portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible.